Therefore, the pharmacological or phytochemical activation of NRF2 mitigates obesity, insulin resistance, and other comorbidities, including cardiac remodeling and fibrosis, as well as diastolic dysfunction, thus improving cardiac dysfunction. This evidence concerns the gene NFE2L2 and obesity due to melanocortin 4 receptor deficiency.